Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

the standard of care. The study found:

-- Up to 81 percent of those patients treated with R1626 1500 mg (twice-

daily) + PEGASYS + COPEGUS had an undetectable HCV viral load by week

four (mean reduction of 5.2 log10 IU/mL)

-- ALT, a liver enzyme, normalized in approximately 50 percent of patients

in R1626 treatment groups

-- Most reported adverse events were mild to moderate. Dose dependent,

reversible grade four neutropenia was observed in the R1626 arms (36

percent in patients receiving R1626 1500 mg + PEGASYS + COPEGUS), and

was the main reason for dose reduction and discontinuation

Lack of Resistance

According to a second presentation at the conference, resistance to R1626 was not identified following intensive testing for either two weeks of treatment with R1626 as monotherapy, or in patients treated with R1626 for four weeks in combination with the standard of care. These findings suggest that there is a high barrier to the development of resistance to R1626 in vivo.

Start of Phase IIb Trial

R1626 is being progressed into Phase IIb study, called POLI 1, to further investigate the new treatment regimens of R1626, in combination with standard or lower dose of PEGASYS and standard dose of COPEGUS. This Phase IIb trial is now open and enrolling patients in eight countries, including the United States. More information about R1626 and the clinical studies can be found on http://www.roche-trials.com.

"As a clinician, I am excited by the high rates of viral negativity that were observed after four weeks of treatment with R1626 in combination with the standard of care. The design of the Phase IIb study should enable us to find the doses of R1626, PEGASYS and COPEGUS that achieve the appropriate balance between safety and efficacy," said Dr. David Nelson, Director of Hepatology and Liver Transplantation at the
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Biomedical Inc. ( www.synapsebiomedical.com ) announced today it ... of its NeuRx DPS® System for ALS patients.  ... enrollment requirement was implanted over a month and ... which is the only medical device approved by ... humanitarian device that obtained approval at the end ...
(Date:9/30/2014)... EXECUTIVE SUMMARY The present report ... - Increasing Demand from Ageing Population to Drive ... past, present and future outlook. The report discusses ... market with outlook to 2017. Statistics include functional ... sub-segments of the industry, ongoing trends and developments, ...
(Date:9/30/2014)... DURHAM, N.C. , Sept. 30, 2014 /PRNewswire/ ... that Viztek LLC (Viztek), a leading provider of ... licensed HeartIT,s zero footprint patent portfolio. The licensed ... to provide access to diagnostic-quality medical images in ... part of the agreement, Viztek and its Subsidiaries ...
Breaking Medicine Technology:Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 2Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 3North America Nutraceuticals Industry Outlook to 2017- Increasing Demand from Ageing Population to Drive Growth 2North America Nutraceuticals Industry Outlook to 2017- Increasing Demand from Ageing Population to Drive Growth 3
(Date:9/30/2014)... at the University of Michigan have described a new ... fraction of the time needed for more traditional methods. ... novel antibody that is undergoing further investigation as a ... , In research published online in the ... researchers in the lab of Stephen Weiss at the ...
(Date:9/30/2014)... Fla. (PRWEB) September 30, 2014 Lea ... is giving breast cancer patients a new, more practical ... , Women who undergo mastectomies, biopsies and lumpectomy surgeries ... promote healing. But after seeing her patients describe the ... compelled to create a new bra in her spare ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Brig Hart, ... history, who broke over 500 Diamond-ranked professionals using his ... doing it again. The Life Support System for ... he has been perfecting using his experiences and successes ... month. Using the principles and methodology taught by Brig ...
(Date:9/30/2014)... Farmington, NY (PRWEB) September 30, 2014 Timber ... design/build process for the Olsen family’s reclaimed Douglas fir ... will cover the home’s journey from architectural planning, to the ... Dee Olsen turned to New Energy Works, after following the ... to design and build their dream vacation home on land ...
(Date:9/30/2014)... September 30, 2014 ... , From:        Hope For The ... abarnwell(at)hopeforthewarriors(dot)org , Event:        Got ... , Date:        Thursday, October 2, ... and Navy Club, 901 ...
Breaking Medicine News(10 mins):Health News:New discovery approach accelerates identification of potential cancer treatments 2Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 2Health News:Surgeon Creates New Bra for Breast Cancer Patients, Post-Surgery 3Health News:Brig Hart Announces the First Diamond Elite Representatives using his Life Support System 2Health News:Brig Hart Announces the First Diamond Elite Representatives using his Life Support System 3Health News:Reclaimed Timber Frame Home By New Energy Works Featured in Timber Home Living Magazine 2Health News:Reclaimed Timber Frame Home By New Energy Works Featured in Timber Home Living Magazine 3Health News:Hope For The Warriors' Got Heart, Give Hope Celebration Media Advisory 2
... , , ... US Oncology, Inc . today announced that US Oncology ... Phase III, Multi-center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin (G/C), with or ... HER2-negative metastatic breast cancer. , , ...
... , , , , ... its online boutique, www.chemo-couture.com , featuring inspirational, handcrafted ... and loved ones. , , Inspired ... disease, Jane Bebita and Julie Uhrig joined forces to create an ...
... , , SEOUL, South Korea, July ... 039350) is pleased to announce that its wholly owned subsidiary, ... for the commercial, institutional, and consumer markets, has successfully turned the ... the world) green! Royal Laundry of South San Francisco ...
... , , , ... Resources, one of the world,s leading research and advisory firms focusing ... market in Brazil will grow from $200 million in 2008 to ... the tumor necrosis factor-alpha (TNF-alpha) inhibitors Abbott,s Humira and Schering-Plough,s Remicade ...
... , , BRIDGEWATER, N.J., ... that it is possible to recruit large numbers of women, ... The study, known as GRACE, is the largest study to ... and race differences in response to an HIV-1 therapy -- ...
... , WHITE PLAINS, N.Y. and CAMBRIDGE, Mass., July ... FORMA Therapeutics today announced a partnership to accelerate LLS,s pipeline of ... , The collaboration will begin with a selection of ... to have the most promise of advancing into clinical trials in ...
Cached Medicine News:Health News:US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201 2Health News:US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201 3Health News:US Oncology Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201 4Health News:HepaHope Korea Subsidiary VASKA Introduces Green Chemicals to U.S. Commercial Laundry Industry 2Health News:Brazil's Rheumatoid Arthritis Drug Market Will Grow $115 Million by 2013 2Health News:New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies 2Health News:New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies 3Health News:New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies 4Health News:New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies 5Health News:New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies 6Health News:New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies 7Health News:New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U.S. HIV Clinical Studies 8Health News:The Leukemia & Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster 2Health News:The Leukemia & Lymphoma Society and FORMA Therapeutics Enter Collaboration to Bring New Therapies to Patients Faster 3
... The AngioJet Xpeedior+120 Rheolytic Thrombectomy catheter is ... performance. Powerful saline jets create a low ... a vacuum effect. Thrombus is drawn into ... the jets, and removed from the body.,AngioJet ...
... combined with a stimulation lead ... Temporary Pacemaker can be used ... pacing is indicated. The device ... as well as diagnostic purposes ...
... a unique left ventricular assist device that helps ... being used in a small group of patients ... of an FDA-approved Feasibility Study. The patient can ... power source for minutes or hours. The Kantrowitz ...
... new Bicycle Ergometer ... braking system which ... reliable service while ... The hyperbolic workload ...
Medicine Products: